Entera Bio Reports Q3 FY23 Earnings, FDA Agrees on BMD as EB613 Endpoint

• Entera Bio reports Q3 2025 financial results • FDA agrees on BMD as primary endpoint for EB613 registrational study • EB613 Phase 2 data shows consistent efficacy in osteoporosis patients • Next-gen EB613 on track for Phase 1 initiation in late 2025 • Pre-clinical data for oral OXM in obesity and GLP-2 in short bowel syndrome presented at ENDO2025 and ESPEN